Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C

Journal of Urology

Volumn 174, Issue 1, 2005, Pages 322-327

  Xin, Yan ^a   Lyness, Greg ^a   Chen, Danny ^a   Song, Saeheum ^a   Wientjes, M Guillaume ^a   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Administration, intravesical; Bladder; Bladder neoplasms; Mitomycin; Suramin

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; MITOMYCIN C; SURAMIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BODY WEIGHT; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

EID: 20444480653     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000161594.86931.ea     Document Type: Article

References (20)

1. Au, J. L., Badalament, R. A., Wientjes, M. G., Young, D. C., Warner, J. A., Venema, P. L. et al: Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst, 93: 597, 2001
2. Wientjes, M. G., Badalament, R. A. and Au, J. L.: Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol, 32: 255, 1993
3. Zhang, Y., Song, S., Yang, F., Au, J. L. and Wientjes, M. G.: Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther, 299: 426, 2001
4. Song, S., Wientjes, M. G., Gan, Y. and Au, J. L.: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA, 97: 8658, 2000
5. Song, S., Wientjes, M. G., Walsh, C. and Au, J. L.: Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res, 61: 6145, 2001
6. Villalona-Calero, M. A., Wientjes, M. G., Otterson, G. A., Kanter, S., Young, D., Murgo, A. J. et al: Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res, 9: 3303, 2003
7. Villalona-Calero, M. A., Otterson, G. A., Wientjes, M. G., Murgo, A., Jensen, R., Yeh, T.-K. et al: Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 41: 149, 2003
8. Allen, L. E. and Maher, P. A.: Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J Cell Physiol, 155: 368, 1993
9. Gan, Y., Mo, Y., Kalns, J. E., Lu, J., Danenberg, K., Danenberg, P. et al: Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res, 7: 1313, 2001
10. Gan, Y., Wientjes, M. G., Schuller, D. E. and Au, J. L.: Pharmacodynamics of taxol in human head and neck tumors. Cancer Res, 56: 2086, 1996
11. Kimura, M., Konno, T., Miyamoto, Y., Kojima, Y. and Maeda, H.: Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. Anticancer Res, 18: 2547, 1998
12. Schmittgen, T. D., Wientjes, M. G., Badalament, R. A. and Au, J. L.: Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res, 51: 3849, 1991
13. Munro, N. P. and Knowles, M. A.: Fibroblast growth factors and their receptors in transitional cell carcinoma. J Urol, 169: 675, 2003
14. Inoue, K., Slaton, J. W., Karashima, T., Yoshikawa, C., Shuin, T., Sweeney, P. et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res, 6: 4866, 2000
15. Izawa, J. I., Slaton, J. W., Kedar, D., Karashima, T., Perrotte, P., Czerniak, B. et al: Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep, 8: 9, 2001
16. O'Brien, T. S., Smith, K., Cranston, D., Fuggle, S., Bicknell, R. and Harris, A. L.: Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol, 76: 311, 1995
17. Miyake, H., Kara, I., Gohji, K., Yoshimura, K., Arakawa, S. and Kamidono, S.: Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett, 123: 121, 1998
18. Rapoport, B. L., Falkson, G., Raats, J. I., de Wet, M., Lotz, B. P. and Potgieter, H. C.: Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study. Ann Oncol, 4: 567, 1993
19. Qiao, L., Pizzolo, J. G. and Melamed, M. R.: Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 carcinoma cells. Biochem Biophys Res Commun, 201: 581, 1994
20. Howard, S. P., Park, S. J., Hughes-Davies, L., Coleman, C. N. and Price, B. D.: Suramin increases p53 protein levels but does not activate the p53 dependent G1 checkpoint. Clin Cancer Res, 2: 269, 1996